Successful bevacizumab therapy in a 25-year-old patient with recurrent respiratory papillomatosis

Authors

• Gita Dambrova Department of Pulmonary Diseases, Pauls Stradins Clinical University hospital, Riga, Latvia; Riga Stradins University, Riga, Latvia
• Zaiga Kravale Department of Pulmonary Diseases, Pauls Stradins Clinical University hospital, Riga, Latvia; Riga Stradins University, Riga, Latvia
• Dace Žentiņa Department of Pulmonary Diseases, Pauls Stradins Clinical University hospital, Riga, Latvia; Riga Stradins University, Riga, Latvia
• Andra Krūmiņa Riga Stradins University, Riga, Latvia; Department of Pulmonary Diseases, Riga East Clinical University Hospital, Riga, Latvia

gita.dambrova@gmail.com

Keywords

Abstract

Background: Recurrent respiratory papillomatosis (RRP) is a chronic condition caused primarily by human papilloma virus (HPV) types 6 and 11, leading to recurrent growths in the respiratory tract. These types of papilloma can cause significant morbidity due to airway obstruction, often requiring frequent surgical interventions. Traditional treatments, including surgical removal and adjunctive therapies like antivirals and immune modulators, often fail to prevent recurrence, impacting the patient’s quality of life.
Case description: This report presents a 25-year-old female with a long-standing history of RRP, diagnosed at age 2. Despite numerous interventions, including CO₂ laser ablations, interferon therapy, HPV vaccination, and a laryngotomy with tracheal reconstruction, the patient continued to experience severe airway obstruction requiring frequent surgeries. In 2023, intravenous therapy with bevacizumab, vascular endothelial growth factor inhibitor was introduced, leading to a significant reduction in the frequency of surgical interventions from 8 to 4 per year. This reduction improved the patient’s respiratory function and quality of life, highlighting bevacizumab’s therapeutic potential.
Conclusion: The case underscores the debilitating nature of RRP and the challenges of its management. Bevacizumab, by targeting vascular endothelial growth factor (VEGF), has shown promise in reducing papilloma growth and the need for frequent surgeries. This case supports the inclusion of bevacizumab as an adjunctive therapy in RRP treatment, warranting further research to confirm its long-term efficacy and safety.

References